Bedaquiline is safe and effective in treating MDR-and XDR-TB patients http://ow.ly/6MWK30adHkw
Introduction 480 000 cases of multidrug-resistant tuberculosis (MDR-TB) and 100 000 cases of rifampicin-resistant (RR)-TB eligible for MDR-TB treatment were estimated by the World Health Organization (WHO) to have occurred in 2015, with 250 000 deaths [1] . Over half of the estimated MDR-TB cases occurred in India, China, the Russian Federation and the other former Soviet Union countries, as well as in South Africa [1] . Globally, ∼10% of the MDR-TB strains meet the criteria defining extensively drug-resistant (XDR)-TB (resistance to any fluoroquinolone and at least one second-line injectable drug) [1, 2] .
Treatment for MDR-and XDR-TB is long, expensive and characterised by a high rate of adverse events [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The main difficulty is the identification of at least four active drugs in order to design an effective regimen [3, 5, 7, 10, 11] .
The prior stepwise approach based on the hierarchical use of first-and second-line anti-TB drugs classified into five groups has been recently modified by the WHO. The new classification includes four groups of drugs (A: fluoroquinolones; B: second-line injectable agents; C: other core second-line agents; and D: add-on agents, subdivided into the subgroups D1, D2 and D3) [5] .
Two newly available drugs, delamanid [12] [13] [14] and bedaquiline [15] [16] [17] [18] [19] [20] [21] [22] , together with some repurposed drugs (linezolid [7, [23] [24] [25] [26] , carbapenems [27] [28] [29] [30] [31] and clofazimine [32] [33] [34] , among others [35, 36] ) are presently pivotal in ongoing scientific discussions.
The information available today on bedaquiline is still limited to phase 2 studies and small individual cohorts treated under clinical trial conditions, the largest study not exceeding 233 patients [15] [16] [17] [18] [19] [20] [21] 37] . In particular, at this present time, no study of size informs us on the effectiveness, safety and tolerability of bedaquiline, in different continents and programmatic conditions. Given the concerns around the adverse events of bedaquiline ( particularly QT prolongation, potentially at highest risk when added to the fluoroquinolones moxifloxacin, levofloxacin and oflofloxacin, clofazimine, delamanid and methadone, among others), additional evidence on its safety, apart from that provided by the registration trials, is urgently needed [38] [39] [40] .
Recently, TB reference centres belonging to the International Bedaquiline Study Group (a network merging the centres belonging to the International Carbapenems Study Group (ICSG) [29] [30] [31] and the European Respiratory Society (ERS)/Asociación Latinoamericana de Tórax (ALAT) and the Brazilian Society of Respiratory Medicine collaborative projects [41, 42] , coordinated by the ERS TB collaborating centre) conducted an observational study on the therapeutic contribution of bedaquiline within a background regimen (as per WHO guidelines) when treating MDR-and XDR-TB cases.
The aim of the present study is to evaluate the safety, tolerability and effectiveness of bedaquiline within background regimens in a large multicentre cohort of MDR-and XDR-TB patients treated under different conditions ( programmatic, expanded access, but not recruited for experimental studies).
Material and methods
The methodological approach adopted for this study is similar to that described in previous ICSG studies [29] [30] [31] . 25 MDR-TB reference centres located in 15 countries in Africa, Asia, Western and Eastern Europe, Oceania and Southern America (Argentina, Australia (Victoria State), Belarus, Belgium, Greece, India, Italy, the Netherlands, Peru, Portugal, Russian Federation (Arkhangelsk and Moscow city), South Africa, Spain, Sweden and United Kingdom) retrospectively collected data on RR-TB and culture-confirmed MDR-TB patients aged ⩾15 years ( figure 1 and online supplementary table S1 ).
An MDR-TB case was defined as an individual with TB disease caused by Mycobacterium tuberculosis strains phenotypically resistant to at least isoniazid and rifampicin. RR-TB cases were those diagnosed using Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) complemented by line probe assays. XDR-TB cases were those whose disease was due to MDR M. tuberculosis strains with additional resistance to any fluoroquinolone and one of the second-line injectable drugs (i.e. amikacin, capreomycin and kanamycin) [1, 5] .
Patients starting their treatment between January 1, 2008 and August 30, 2016 were consecutively enrolled based on their exposure to bedaquiline during the intensive and continuation phases. We included in the study only patients exposed to bedaquiline-containing regimens, without considering the date of exposure. The condition was that bedaquiline had to be added within the design of the last treatment course.
An individualised TB regimen was administered following the results of drug susceptibility testing (DST) performed by externally quality-assured laboratories [29] [30] [31] . RR-TB cases were managed according to the national guidelines in force in their respective countries (e.g. South Africa) [43] .
Physicians were free to prescribe the accompanying anti-TB treatment to obtain the best possible regimen in their setting and, consequently, no specific protocol or method beyond local guidelines was followed.
Bedaquiline was administered at the recommended dose of 400 mg once a day for 14 days, then 200 mg three times a week for 22 weeks. It was prescribed under programmatic conditions, expanded access and compassionate use, but not under the experimental protocols of clinical trials. Adverse events were attributed to bedaquiline or to another particular drug by local attending physicians and local teams (with support of a local TB consilium, where available), without any standardised protocols or documented level of ascertainment of the causal association. A standardised classification for the severity of the adverse events was not used.
A standardised ad hoc e-form was used to collect epidemiological (i.e. age; place of birth and residence; sex; and migrant status from a TB high-incidence country), clinical (i.e. cardiac and thyroid disorders; HIV testing; HIV infection status; administration of HIV drugs; previous TB diagnosis and treatment; previous treatment outcomes; radiological findings; TB therapy and related adverse events; duration of exposure to bedaquiline, delamanid, linezolid or carbapenems; adjuvant surgery; sputum smear and culture positivity at baseline; and during treatment at 30, 60 and 90 days, time to sputum smear and culture conversion; WHO treatment outcomes; and duration of hospital stay) and microbiological (i.e. DST results) data from medical records. Culture conversion rates were calculated, including in the numerator the patients with a negative culture, and in the denominator the patients completing treatment including failures, but excluding death and default outcomes.
As the latest WHO outcome definitions were introduced in 2013 and our first cohort was treated in 2008, we kept the outcome "default" instead of "lost to follow-up" [5] .
With regard to the analysis of treatment outcomes, a subanalysis of MDR-TB patients who started their treatment before December 31, 2014 was performed in order to include those who could fit the definition of treatment completion and cure according to the WHO guidelines on MDR-TB treatment [5] .
A homogeneous and standardised approach to DST was not possible in all the clinical centres. The percentages reported for resistance have been calculated according to the number of cases tested for (denominator) and the number of cases resistant to (numerator) a specific drug.
Ethical approval for the retrospective collection of clinical data was obtained by the coordinating centre. The centres involved in the study requested the authorisation for the treatment of their patients according to national legislation, and, accordingly, a consent form was signed by the patient and the attending physician.
The map in figure 1 was created using the rworldmap package (www.r-project.org) [44] .
Qualitative and quantitative variables were summarised using percentages and medians (interquartile range (IQR)). Chi-squared or Fisher exact tests were used to compare qualitative variables, and the MannWhitney test was used to statistically compare quantitative variables. A p-value of <0.05 was considered statistically significant. Statistical computations were performed using Stata 13.0 (StataCorp, College Station, TX, USA).
Results

Patient characteristics
Demographic, epidemiological and clinical characteristics of the patients are summarised in table 1 and figure 1; safety and tolerability information on bedaquiline-containing regimens in table 2; and treatment outcome results in tables 3 and 4. 428 culture-confirmed MDR-TB patients were recruited (figure 1 and online supplementary table S1). The most prevalent sex in the cohort was male (n=263, 61.5%) and the median (IQR) age was 35 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) years. The characteristics of the 428 culture-confirmed MDR-TB patients are summarised in table 1. There were 45 (10.5%) migrants from countries with high TB incidence to those with low TB incidence.
The proportion of HIV co-infected patients was 22.1%; their median (IQR) CD4 cell count was 269 (168-470) cells·mm −3 and the majority (n=92, 97.9%) received antiretroviral therapy. HIV co-infection prevalence in Africa, Eastern Europe and remaining settings was 88 (46.3%) out of 190, 0 (0%) out of 150 and 6 (7.1%) out of 85, respectively.
Pulmonary TB was diagnosed in 426 (99.5%) out of 428 cases; the extrapulmonary locations being abdominal and the nervous system (n=2). The percentages of sputum smear-and culture-positive cases were 72.1% and 98.4%, respectively.
Fewer than half the patients were affected by XDR-TB (195/428, 45.6%), with a median (IQR) number of drug resistances of 3 (1-5). Overall, 334 (78.0%) out of 428 cases had been treated previously for TB. The median (IQR) range of the administrative delay in procuring bedaquiline was 8 (0-60) days.
Patients were exposed to bedaquiline for a median (IQR) of 168 (86-180) days (table 2) . Five (1.2%) patients underwent treatment with both delamanid and bedaquiline. Adjuvant surgical therapy was performed in 55 (13%) cases.
The median (IQR range) treatment duration in the cohort was 18 (10-22) months.
Adverse events
The majority of the adverse events reported were nausea, peripheral neuropathy and otovestibular toxicity. Adverse events potentially attributed to bedaquiline were reported in 80 (19.4%) out of 413 cases where this information was provided (table 2) .
In particular, 51 (11.9%) out of 428 patients discontinued bedaquiline (25 (5.8%) of whom reported adverse events); of these 26 (51%) did so permanently.
Although we do not have the exact information on how many patients interrupted bedaquiline due to Fridericia-corrected QT interval (QTcF) increase, 24 (9.7%) out of 247 patients experienced QTcF prolongation >500 ms.
One patient was started on bedaquiline with a baseline QTcF of 553 ms, which then decreased to 536 ms at week 4 and 554 ms at week 8. A second patient, with a baseline QTcF of 352 ms, had a transient increase (510 ms at week 3) followed by a decline (358 ms at week 4); she was palliated at home as per her request. She had had no arrhythmias at any point and no evidence to suggest that her death was related to a cardiovascular event. She achieved sputum conversion (smear and culture) prior to her death. According to the information available, a single case out of 33 who died had ECG abnormalities. During bedaquiline treatment the patient had a single QTcF measurement >450 ms, but <500 ms. This patient reported to the primary health centre 2 days before death complaining of weakness. The coordinating centre suggested drawing blood for electrolyte analysis, which revealed hypokalaemia. Thus, the patient was transferred to the district hospital where ECG showed premature ventricular complex bigeminy and then irreversible cardiac arrest. He died after 131 days of treatment with bedaquiline. The final ECG showed QTcF <450 ms. Thus, a relationship between bedaquiline use and fatal arrhythmia seems unlikely following revision of the clinical and ECG history of the patient.
Furthermore, 104 (29.9%) out of 348 cases treated with linezolid reported adverse events attributed to this drug by the attending physician; 16 (27.6%) out of 58 of them (for whom final treatment outcome was available) permanently discontinued linezolid.
Sputum conversion and treatment outcomes
Sputum smear and culture conversion rates were 63.6% and 30.1%, respectively at 30 days; 81.1% and 56.7%, respectively at 60 days; 85.5% and 80.5%, respectively at 90 days and 88.7% and 91.2%, respectively at the end of the MDR-TB treatment (for those completing it) respectively. The median (IQR) time to sputum smear and culture conversion was 34 (30-60) days and 60 (33-90) days, respectively (figure 3).
Out of 247 culture-confirmed MDR-TB cases that completed treatment, 71.3% achieved success (62.4% cured and 8.9% completed treatment), 13.4% died, 7.3% defaulted and 7.7% failed ( Data are presented as n/N (%), median (interquartile range) or mean±SD, unless otherwise stated. Sputum smear and culture conversion rates at the end of treatment were not significantly different between XDR-and MDR-TB cases ( p=0.73 and 0.96, respectively).
The treatment success rates for MDR-and XDR-TB patients were higher in Eastern Europe and in settings other than in Africa; table 4 summarises the treatment outcome by cohort.
Discussion
The aim of the present study was to retrospectively evaluate the effectiveness, safety and tolerability of bedaquiline-containing regimens in a large observational cohort of MDR-and XDR-TB patients treated under different conditions ( programmatic, expanded access, but not recruited for experimental studies).
To our knowledge, this is the largest study describing how safe, well tolerated and effective bedaquiline is within background regimens and the first in the scientific literature reporting on the nonclinical trial use of bedaquiline for the treatment of MDR-and XDR-TB patients in five continents.
In comparison with the data on individual patient data analysis (where there was a 43% success in XDR-TB) [3] , in our bedaquiline-treated XDR-TB cohort the success rate was 71.3%.
In a phase 2 double blind, randomised controlled trial study by DIACON et al. [16] the median time to culture conversion in 79 bedaquiline-treated MDR-TB patients was 83 days; this compares with our median time of 60 days. In the study by DIACON et al. the culture conversion at the end of 24 weeks was 79% and at 120 weeks was 58% versus 91.7% at the end of therapy in our study, and the cure rates were 58% and 62.4%, respectively [16] . Regarding effectiveness, although difficult to attribute to bedaquiline, we can report that bedaquiline-containing regimens achieved culture conversion rates >90% at the end of treatment and treatment success >70% (76.7% when only calculating patients who started their treatment before December 31, 2014), higher than those observed in other MDR-TB cohorts [3, 15, 17] . PYM et al. [15] conducted a phase 2 trial to assess the safety and efficacy of bedaquiline in 233 patients; culture conversion was seen in 72.2% at 120 weeks, 8.6% of patients discontinued treatment and 6.9% of patients died [15] .
Regarding safety, in the study by DIACON et al. [16] , 13% of patients in the bedaquiline group died (10 out of 79 versus two out of 81 in the placebo group) versus a very similar 33 (13.4%) out of the 247 who had an evaluable outcome in our cohort.
The most frequent adverse events in our study were nausea (31.5%), otovestibular toxicity (23.3%), peripheral neuropathy (23.3%), vomiting (21.2%), anaemia (20.9%) and arthralgia (20.4%), their frequencies being slightly lower than those described during the licensing study by DIACON et al. (41% nausea, 29% vomiting and 37% arthralgia) [17] . Importantly, in the study by DIACON et al. the proportions of adverse events were similar in the treatment group versus placebo patients, suggesting that they were probably due to the background regimen. In this context, other second-line drugs such as fluoroquinolones or clofazimine might contribute to cardiologic or other adverse events [10, 11, 32] , and invite caution and ECG monitoring.
The results of our study demonstrate that overall, bedaquiline-containing regimens achieve a relatively higher proportion of treatment success with a relatively lower proportion of adverse events within different settings than previously described, although a standardised approach for the notification of the adverse events was not implemented across the different settings (risk of underreporting).
Of note, culture conversion rates were higher than those reported in cohorts with an analogous degree of disease severity, with time to sputum smear and culture conversion identical or earlier to those observed in comparable cohorts; the proportion of treatment success was higher, and the percentage of adverse outcomes (death or failure) lower than those seen in available study cohorts with matching disease severity; adverse events due to bedaquiline leading to interruption of the drug were relatively uncommon (5.8%) [10, 11] .
Our study confirms that bedaquiline-containing regimens are effective, as demonstrated by the fact that a sizeable number of patients were treated with salvage regimens due to previous treatment failure, unfavourable resistance profile, toxicity or all three.
The larger group of patients in different nonclinical trial conditions around the globe reinforces previous findings that bedaquiline is well tolerated and adverse events might be less common than previously thought.
Enthusiasm over bedaquiline and delamanid has been curtailed following concerns of potential cardiotoxicity. Both new drugs are associated with QT prolongation, which may potentially lead to arrhythmia and sudden death, a major reason why their combination has not been recommended. Moreover, the new drugs are likely to be associated with a fluoroquinolone and clofazimine, both known to prolong QT intervals. The specific role of the many drugs with QT-prolonging potential (and their summation or synergistic effect) still needs to be fully understood.
QT prolongation occurred in 9.7% of patients; interruption of bedaquiline due to adverse events occurred in 25 (5.8%) patients.
Although information on QT interval was available in 64% of cases, and the timing of their assessment not standardised, it seems the majority of cases died for non-heart-related reasons. A more accurate assessment of the adverse events (from data collection to detailed clinical investigation) will allow the evaluation of the relationship between death and QT prolongation. Unfortunately, our data are not standardised and therefore heterogeneous.
Close monitoring of drug safety should be implemented widely, particularly for rare adverse events. A comprehensive, population-level pharmacological surveillance in the post-marketing phase might allow a better assessment of the safety and tolerability profile of bedaquiline, alone or in combination with other potentially cardiotoxic anti-TB drugs [45] .
The importance of implementing active TB drug-safety monitoring and management when bedaquiline is used programmatically cannot be overemphasised [45] .
We underline the importance of using, in future studies, a standardised ECG monitoring protocol allowing to exclude inter-and intra-day variability in QTc measurements. For study purposes, 24-h Holter monitoring is probably the best strategy to assess the true impact of drugs on QTc. Clearly, this is not feasible under programmatic conditions.
The strengths of the study are the large cohort, the inclusion of cases from several countries (ranging from 7.7% of all patients receiving bedaquiline in the UK to 100% of bedaquiline-treated patients in Argentina, Australia (Victoria State), Greece, Peru, Russian Federation (Arkhangelsk oblast) and Spain) and the detailed information collected from the participating centres. The large sample size allows the comparison of treatment outcomes from different settings for the first time.
Some variables, such as the drug-resistance patterns, the number of previous anti-TB treatment cycles and HIV seroprevalence varied between the settings participating in the study.
However, the observational and retrospective design of the study has inbuilt limitations (recent guideline changes, different resource settings, different standards of care and dataset differences), so the research findings need to be confirmed by larger randomised controlled clinical trials and well-designed prospective observational studies.
Furthermore, several sources of bias may confound the reliability of the findings: missing random selectivity of the patients, heterogeneity between recruited geographic settings, different levels of completeness of collected data (especially adverse events and their severity), nonstandardised DST methods for several drugs, background regimen variability between countries which differed over time (mainly later generation fluoroquinolones), different TB/HIV co-infection prevalence and availability of antiretroviral drugs.
The effectiveness of bedaquiline might be overestimated, owing to the additive and/or synergistic role played by other effective drugs (e.g. carbapenems, linezolid, etc.) [7, [23] [24] [25] [27] [28] [29] [30] [31] . New experimental studies should be implemented to assess the critical effect of bedaquiline, as well as delamanid, in new combination therapies.
The different operating procedures adopted in various settings, as well as heterogeneous drug resistance patterns, may underestimate the real benefits of the bedaquiline-containing regimens.
However, stratified analyses allowed us to better assess the heterogeneity related to time and geographical factors. The new information provided by this observational study allows clinicians managing difficult-to-treat TB cases in programmatic conditions to better understand how to use bedaquiline in case the minimum number of active drugs necessary to design an effective regimen is lacking [1, 5, 11] .
Although new compounds will soon become available to support the move towards TB elimination [46] , this study confirms the "core drug" characteristics of bedaquiline in the management of MDR-and XDR-TB cases even in field conditions, and eventually for use in newly designed anti-TB regimens of the future.
While it is crucial to recommend the use of bedaquiline in difficult-to-treat cases, WHO guidelines should be followed assiduously in order to limit the emergence and spread of bedaquiline-resistant M. tuberculosis strains.
